Molecular subtype based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) has established the foundation for individualized breast cancer treatment [4]. This evidence concerns the gene ERBB2 and breast carcinoma.